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The Inextricable Link: 
Service-Academic Partnership for 
the Public’s Health
Gabriel M Leung
Agenda
• Grand Challenges 
– Lost in Translation?
• Health Protection
• Health Improvement
• Health Services and Systems
Grand Challenges – Lost in Translation ?
Grand Challenge 1 in Clinical Science
J Translat Med 2004;2:35
• How could one best translate research (especially in basic science) 
into clinical practice?
• A question of multi-directional technology transfer between:
– laboratory and bedside Æ improved health
Grand Challenge 2 in Clinical Science
• Also a question of multi-directional technology transfer 
between:
– academia and industry Æ improved wealth
• Emphasis of value creation from the production of 
knowledge through research
• Facilitated over the years by:
– legislation – Bayh-Dole Act (1984) in US and Allègre Innovation 
Laws (1999) in France, giving institutions performing publicly 
funded research IP rights, thus potential financial gains
– commercial arms of research bodies – MRC Technology Co., 
INSERM Transfert, NIH Roadmap-Clinical and Translational 
Science Awards 
– funding – public, pharma and venture capital
• Whither Hong Kong, China and indeed much of Asia?
• How should we incentivise innovation?
IOM Clinical Research Roundtable 
JAMA 2003;289:1278-87
“Even if we stop all research today, we’d still be improving clinical care 
for the next 20 years bringing to practice all that we already know.”
– a former president of RCP (London)
「議 (研 )而不決
決而不行」
-朱鎔基
The Missing Link
Parallel Grand Challenge 
in Translational Public Health
• Little good comes of best, current evidence unless it is 
translated into public health policy, and the interventions 
then implemented expeditiously and effectively
• “Struggles with human behaviour and organisational
inertia, infrastructure and resource constraints, and the 
messiness of proving the effectiveness of ‘moving 
targets’ under conditions that investigators cannot fully 
control”
• “Mastery of the ‘implementation science’ of fielding and 
evaluating interventions in real world settings and of the 
disciplines that inform the design of those interventions, 
such as clinical epidemiology and evidence synthesis, 
communication theory, behavioral science, public policy, 
financing, organizational theory, system redesign, 
informatics, and mixed methods/qualitative research”
JAMA 2008;299:211-3
Grand Challenge in Translational Public Health
• Prerequisite: playing matchmaker between government 
and academics
• TRIP (Translating Research into Practice) grants from 
AHRQ in US; Studies in Health Services by HHSRF; 
Public Policy Research by RGC; some RFCID 
commissioned grants
– however the invested amounts pale in comparison to those 
devoted to the clinical science grand challenges
– “Disproportion has consequences, and the current policy of 
spending 1.5% (US) or 3.4% (HK) of (biomedical) research 
dollars on health services research is probably costing lives”
(JAMA 2008;299:221-3; UGC/RGC, RFCID and HHSRF statistics)
Are there examples of translational public health 
in action locally ?
• Health Protection
• Health Improvement
• Health Services and Systems
Health Protection 
– standing on guard for thee

2 plausible but very different scenarios are 
consistent with current data: JE in HK
Data from field studies are required before
success of swine vaccination can be evaluated  
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Start vaccination1
1) 2 doses: one at day 
55 and the other at day 
83. Both doses to be 
100% effective on 
piglets not protected by 
maternal antibodies. 
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Average age loss of maternal antibodies
Difference in vaccine efficacy largely driven by 
different average ages of infection
A longitudinal study of piglet viraemia could be 
used to distinguish between these scenarios   
1) 2 doses: one at day 
55 and the other at day 
83. Both doses to be 
100% effective on 
piglets not protected by 
maternal antibodies. 
Start vaccination1
Pandemic Influenza Mitigation Tripod
Non-
pharmaceutical 
interventions
Vaccines
Anti-virals
Public health interventions
Symptomatic attack rates could be reduced 
substantially by these interventions
Symptomatic 
attack rate
Peak 
prevalence of 
quarantine
Peak 
prevalence 
of isolation
Anti-viral 
doses 
required
Baseline (no intervention) 49% - 1.4% 0.9
Quarantine 33% 9.8% 0.6% 0.6
Quarantine and isolation 29% 7.3% 0.9% 1.2
Quarantine and anti-virals 29% 8.2% 0.5% 3.9
Quarantine, isolation and anti-
virals 27% 6.4% 0.8% 3.9
Quarantine, isolation, anti-virals 
and contact tracing 23% 14.0% 0.6% 9.9
??
Countries that have approved/implemented 
universal HPV vaccination
Girls (age) Boys (age) Girls (age) Boys (age)
USA 11-12 13-26
Germany 12-17
France 14 up to 23
Italy 12
Norway 11-12 13-16
Australia 12-13 13-26
Belgium 10-13 up to 15
Sweden 13-17
Switzerland 11-14 15-19
Canada* 9-13 14-26
Spain 11-14
Demark 12 up to 15
Portugal 12-16
Luxemburg 11-12 13-18
Austria 9-15 9-15
Greece 12-15
UK† 12-13 up to 18
Primary cohort Catch-up cohort
Should HK follow suit ?
Cervical Cancer Prevention
• Comparator of status quo
– Does        work?
• process measures (average and distribution of coverage)
– Will it work?
• modelling (2 different approaches)
• cytology or HPV testing; and in what order?
• Marginal economic analysis
– What does add, in terms of QALYs?
– At what cost? Who should pay?
– Is it acceptable to girls (boys), parents and the 
general public?
Health Improvement 
– adding years to life, and life to years
Children of 1997 – the study
Collaboration between
1. The University of Hong Kong
2. Department of Health
All births in Hong Kong in April and 
May 1997
1. 8327 infants participated, 
recruited through all MCHCs
2. Interviewed at 3, 9 and 18 
months
Designed to answer many, 
many questions 
1. Smoking (in utero & 
postpartum)
2. Breastfeeding
3. Method of delivery
…& health care use
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Infant SHS exposure 
before and after birth 
among non-smoking 
mothers (95.4% of 
sample)
The “Marlboro” (not 
Mozart) effect
Health and Economic Consequences
• The cost of inpatient and outpatient care (excluding 
preventive care episodes) for an annual cohort of infants 
in the first year of life attributable to SHS is conservatively 
estimated to be >HK$30M
• This is about 10% of the total cost of direct medical care 
for these infants
Moderating effect of smoking hygiene
Policy implications
• Broadens the issue from solely maternal 
smoking in pregnancy to that of the 
whole household
• Directly informed the debate on 2007 
enactment of the Smoking (Public 
Health) Ordinance
• Suggests that targeted smoking 
cessation programmes for fathers and 
other family members during pregnancy 
may be useful (vide Sophia Chan’s work)
• Smoking hygiene can be a possible harm 
reduction interim measure
Controversy, Confusion and Obfuscation…
Food industry-supported 
pressure group infomercials
News headlines
Why ? – Life time perspective 
20yrs 30yrs 40yrs 50yrs 60yrs 70yrs 80yrs
Person with more fat at 
age 40 has fewer years 
of life to live
Both people are equally fat at age 60, 
but different length of life ahead, so 
being fat at 60 appears unrelated to 
survival
At age 70, the person who is 
currently thinner has
a shorter remaining lifespan, 
so being fat at 70 appears 
protective
Life time 
thin person
Thin, gets fat, 
gets ills at 50, 
loses weight 
from illness
Do changes in weight and body composition due to ill-health at 
older ages bias these comparisons?
Hong Kong Elderly Health Cohort
•Provide health examinations and 
primary care services for older adults 
throughout Hong Kong at 18 Elderly 
Health Centers
•Enrollees from 1998 to 2000
•~5% coverage of total elderly pop’n
•96% (N=54,088) followed up from 
enrollment to 31st December 2003
•Average follow-up = 4.1 years 
•Average age at enrollment = 73 years
Obesity affects mortality in healthy and 
unhealthy older people differently
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* Obese people compared with normal weight people with the 
same number of health problems,  adjusted for other differences
For older 
people in 
good 
health, 
54% higher 
risk of 
death in 
obese 
compared 
with normal 
weight
Physical activity in healthy and unhealthy 
older people
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* Inactive people compared with physically active 
people with the same number of health problems
Public Health Implications
• Research suggesting that fatness is not a risk factor and that 
physical activity does not matter for mortality is biased
• Obesity and inactivity c(w)ould become an overwhelming 
public health problem in China 
• Interventions to prevent obesity at all ages are needed now
• BMI (weight and height) alone is an imperfect measure of 
health risk, and should be supplemented by waist 
circumference, waist-hip ratio, % body fat, especially in older 
adults.  EHS has already started to measure some of these 
routinely. 
Health Services and Systems 
– somewhere over rainbow…
(perhaps) lies the promised land
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Thank You…(in order of appearance)
• Research collaborators: Steven Riley (JE), Joe 
Wu (PanFlu), Ben Cowling (NPI), Pauline Woo 
(HPV), TH Lam (“Children of 1997”), Mary 
Schooling (EHS cohort), Keith Tin (health 
financing)
• Sponsors: RFCID (commissioned projects and 
investigator-initiated grants), US CDC, HHSRF, 
FHB
• Translational partners: CHP; HA; EHS, DH; FHB
To us, knowledge, how good and lovely soever it be for its 
own sake, must always be a by-end, a step merely 
towards the still better and lovelier goal of "good-will 
towards men." 
Our object, then, in reviewing these researchers, and in 
adding to them such observations as our own sphere of 
action supplies, should be to deduce from them rules of 
practice, to gather from the tree of knowledge fruit for the 
solace and refreshment of mankind.
Thomas King Chambers
Goulstonian Lecture, RCP, 1850
